Have a personal or library account? Click to login
Levetiracetam as second-line treatment of status epilepticus – which dose should be applied? Cover

Levetiracetam as second-line treatment of status epilepticus – which dose should be applied?

Journal of Epileptology
Volume 29 (2021): Issue 1 (July 2021)
By: Johannes Rösche and  Bernd Schade  
Open Access
|Jul 2021

Authors

Johannes Rösche

RoescheJ@t-online.de

Hephata Klinik, Schwalmstadt, German
Klinik und Poliklinik für Neurologie Universitätsmedizin Rostock, Schwalmstadt, German

Bernd Schade

Hephata Klinik, Schwalmstadt, German
DOI: https://doi.org/10.21307/joepi-2021-001 | Journal eISSN: 2299-9728 | Journal ISSN: 2300-0147
Journal RSS Feed
Language: English
Page range: 7 - 12
Submitted on: May 21, 2021
|
Accepted on: Jul 15, 2021
|
Published on: Jul 27, 2021
Published by: The Foundation of Epileptology
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
levetiracetam,
weight-based dosage,
second-line treatment,
efficacy rate
Related subjects:
Medicine,
Clinical medicine,
Clinical medicine, other,
Neurology,
Pharmacology, toxicology,
Pharmacy,
Clinical pharmacy

© 2021 Johannes Rösche, Bernd Schade, published by The Foundation of Epileptology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Volume 29 (2021): Issue 1 (July 2021)Next article